Gland Pharma announced its financial results for the second quarter ended September 30, 2026 (Q2 FY27), showcasing robust performance. The company reported a 23% year-on-year increase in revenue, reaching ₹18,336 million. Profit After Tax (PAT) saw an even more substantial surge of 58% year-on-year, amounting to ₹2,908 million. The strong growth was attributed to effective execution across its business segments.
Gland Pharma Reports Strong Q2 FY27 Performance
Gland Pharma Limited has announced its financial results for the second quarter and half-year ended September 30, 2026. The company demonstrated significant year-on-year growth across key financial metrics.
Consolidated Financial Highlights
- Revenue from operations increased by 23% year-on-year to ₹18,336 million in Q2 FY27, compared to ₹14,869 million in Q2 FY26.
- Gross Profit grew by 25% year-on-year to ₹11,638 million.
- EBITDA saw a substantial increase of 53% year-on-year, reaching ₹4,804 million.
- Adjusted EBITDA (Adj. EBITDA) rose by 50% year-on-year to ₹5,030 million.
- Profit Before Tax (PBT) increased by 52% year-on-year to ₹4,309 million.
- Profit After Tax (PAT) surged by 58% year-on-year to ₹2,908 million, from ₹1,837 million in the prior year period.
- PAT margin improved to 16% in Q2 FY27 from 12% in Q2 FY26.
Business Performance Drivers
Mr. Srinivas Sadu, Executive Chairman of Gland Pharma, highlighted the strong growth driven by effective execution across businesses. The CDMO business grew by 31% year-on-year, supported by expanding customer engagements, strategic partnerships, and a robust opportunity pipeline. The Critical Injectables business contributed 55% of revenues and grew by 18% year-on-year.
Geographical and Segmental Performance
The company saw strong performance in key markets, with the USA market revenue growing by 42% year-on-year. Europe also showed positive growth with revenue up by 30% year-on-year. The company also detailed its business updates, including new product launches and R&D investments.
The financial results indicate a positive trajectory for Gland Pharma, driven by both revenue growth and improved profitability.
Source: BSE
